Advances in Brief

Receptor for Interleukin 13 on AIDS-associated Kaposi’s Sarcoma Cells Serves as a New Target for a Potent Pseudomonas Exotoxin-based Chimeric Toxin Protein

Syed R. Husain, Nicholas I. Obiri, Parkash Gill, Tong Zheng, Ira Pastan, Waldemar Debinski, and Raj K. Puri

Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892 [S. R. H., N. I. O., R. K. P.]; University of Southern California School of Medicine, Los Angeles, California 90033 [P. G., T. Z.]; Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892 [I. P.]; and Division of Neurosurgery, The Pennsylvania State University College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033 [W. D.]

Abstract

AIDS-associated Kaposi’s sarcoma (AIDS-KS), the most common malignant complication of human immunodeficiency virus infection, is characterized by neoplastic proliferation of mesenchymal cells. AIDS-KS cells release and respond to an array of cytokines through specific plasma membrane receptors. Specific targeting of potent cytokotopic agents to cell surface receptors/antigens on Kaposi’s sarcoma cells may provide effective therapy for this malignancy. We have identified a new target in the form of an interleukin 13 (IL-13) receptor that is overexpressed in the five AIDS-KS cell lines examined. Radiolabeled IL-13 cross-linked to a single protein of about Mr 70,000 in AIDS-KS cells. We utilized a chimeric cytotoxic protein composed of IL-13 and a truncated Pseudomonas exotoxin (IL13-PE38QQR), which was found to be specifically and highly cytotoxic to AIDS-KS cells, as determined by protein synthesis inhibition and clonogenic assays. IL13-PE38QQR demonstrated significant antitumor activity in a human epidermoid carcinoma xenograft model. Normal human umbilical vein-derived endothelial, lymphoid, and bone marrow precursors expressed low levels of IL-13 receptors, and IL-13 toxin was not cytotoxic to them. Thus, IL-13 receptor on AIDS-KS cells may represent a novel plasma membrane protein(s) that could be utilized to target therapeutic agents.

Introduction

AIDS-KS is composed predominantly of proliferating spindle-like tumor cells (1, 2). AIDS-KS cells can produce and respond to a variety of potent cytokines and growth factors (3–8). Chief among these are acidic and basic fibroblast growth factor, granulocyte macrophage colony-stimulating factor, platelet-derived growth factor, transforming growth factor β, IL-1, and IL-6 (8–10). The ability of AIDS-KS cells to constitutively release and respond to the array of cytokines suggests a possible cytokine autocrine growth loop in the AIDS-KS etiology (5, 8). The effect of growth factors and cytokines are mediated through their plasma membrane receptors. KS cells have been reported to express receptors for platelet-derived growth factor α and β, IL-6, oncostatin M, and other factors (2).

We have observed that AIDS-KS-derived spindle cells express high-affinity IL-4R (11). IL-4, a pleiotropic immunoregulatory cytokine, shares many biological functions with IL-13, another predominantly Th2-derived immunoregulatory cytokine (12, 13). IL-13, like IL-4, has also been shown to suppress HIV-1 replication in human monocyte-derived macrophages (14, 15). Furthermore, we and others have reported recently that the receptors for IL-4 and IL-13 may share a component(s) (16, 17). Because AIDS-KS cells expressed IL-4R, and cytokines play a critical role in the pathogenesis of AIDS-KS, we investigated whether AIDS-KS cells express IL-13R. We further investigated whether IL-13R expressed on AIDS-KS cells can be targeted with a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin (termed IL13-PE38QQR; Refs. 18–20).

Materials and Methods

Cell Culture and Reagents. AIDS-KS-derived spindle cells (KS248, NCB-59, KSSA, KS220B, and AR-13) were generated from fresh KS tissues obtained from different HIV-positive patients at the University of Southern California School of Medicine hospitals (Los Angeles, CA) in Dr. P. Gill’s laboratory, as described previously (21). These cells were grown in 1% gelatin-coated flasks in RPMI supplemented with 15% fetal bovine serum, 2 mM glutamine, essential and nonessential amino acids (1 mm). 1% Nutridoma-HU (Boehringer Mannheim, Indianapolis, IN), penicillin (100 units/ml), and streptomycin (100 µg/ml; BioWhittaker, Walkersville, MD).

Human CD34+ bone marrow precursor cells were obtained from Drs. J. Mule and J. Hirth of the University of Michigan (Ann...
Fig. 1 Expression of IL-13R on AIDS-KS cells. The binding of $^{125}$I-labeled IL-13 was performed as described in "Materials and Methods." The data shown here are for the KS248 cell line and are representative of multiple experiments for each AIDS-KS cell line. Mean number of binding sites and receptor affinity for each cell line are summarized in Table I. The displacement curve (A) and Scatchard analysis (B) were generated from the binding data using the LIGAND program (26). C, competitive binding assay on NCB-59. Data are expressed as actual $^{125}$I-labeled IL-13 bound (cpm) to cells in the presence of an increasing concentration of either IL-13 or IL-4. The points are the mean ± SD of duplicate determinations, and the experiment was repeated for this and the KS248 cell line with similar results. NCB-59 cells (1 × 10$^6$) incorporated 14,893 ± 188 (cpm ± SD) in the absence of IL-13 or IL-4. D, IL-13R subunit structure on AIDS-KS cells. Cross-linking of IL-13R on KS248 and NCB-59 was performed as described in "Materials and Methods." The SDS-polyacrylamide gel was dried and exposed to X-ray film for 10 days. The positions of standard molecular weight markers in thousands are shown on the left. Arrows, the specific IL-13R band.

Arbor, MI). The cells were activated in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum in the presence of IL-3 (10 ng/ml), IL-6 (10 ng/ml), granulocyte macrophage colony-stimulating factor (10 ng/ml), and stem cell factor (50 ng/ml) overnight prior to the incubation with IL13-PE38QQR.

Recombinant human IL-4 was provided kindly by Schering Corp. (Kenilworth, NJ). IL-13 was expressed in Escherichia coli and purified by one of us (W. D.). Prior to use, we compared IL-13 produced by us and the one obtained from Dr. A. Minty (Sanofi Elf Bio Recherches, Laberge, France). IL-13 from both sources were found to be identical in biological activity (i.e., support of TF-1-cell proliferation) as well as in their ability to displace $^{125}$I-labeled IL-13 from a cell surface. A polyclonal rabbit antibody (P7) to the p140 form of the human IL-4R was a kind gift from the Immunex Corp. (Seattle, WA).

Radioreceptor Binding. Recombinant human IL-13 was labeled with $^{125}$I (Amersham Corp.) by using IODO-GEN reagent (Pierce Chemical Co.) according to the manufacturer's instructions. The specific activity of radiolabeled IL-13 ranged from 20 to 147 μCi/μg protein. The binding of $^{125}$I-labeled IL-13 was measured by the method described previously (16). Briefly, AIDS-KS cells (0.5 × 10$^6$) were incubated at 4°C for
Table 1: IL-13R on human AIDS-KS and normal cell lines and cytotoxic activity of IL13-PE38QQR

IL13-PE38QQR (474 amino acid protein) is composed of IL-13 (114 N-terminal amino acids) and domain II and domain III of PE molecule (18). Cytotoxicity of IL13-PE38QQR was performed as described in “Materials and Methods.”

<table>
<thead>
<tr>
<th>Cell type</th>
<th>IL-13 binding sites/cell</th>
<th>Kd (pm)</th>
<th>IC50 (ng/ml)</th>
<th>Ref. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS-KS</td>
<td>14452 ± 288</td>
<td>365 ± 121</td>
<td>3 ± 1</td>
<td></td>
</tr>
<tr>
<td>KS-248</td>
<td>7962 ± 35</td>
<td>525 ± 241</td>
<td>8 ± 1</td>
<td></td>
</tr>
<tr>
<td>NCB-59</td>
<td>5,774</td>
<td>124</td>
<td>15 ± 9</td>
<td></td>
</tr>
<tr>
<td>KS220B</td>
<td>5651 ± 934</td>
<td>484 ± 79</td>
<td>137 ± 40</td>
<td></td>
</tr>
<tr>
<td>KS54A</td>
<td>2413 ± 643</td>
<td>428 ± 64</td>
<td>270 ± 50</td>
<td></td>
</tr>
<tr>
<td>Normal cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HUVEC (endothelial)</td>
<td>&lt;200</td>
<td>–</td>
<td>&gt;1000</td>
<td></td>
</tr>
<tr>
<td>CD34*</td>
<td>ND*</td>
<td></td>
<td>&gt;1000</td>
<td></td>
</tr>
<tr>
<td>H9 T cells (T lymphocytes)</td>
<td>UD*</td>
<td></td>
<td>&gt;1000</td>
<td>16, 20</td>
</tr>
<tr>
<td>DH (EBV B cells)</td>
<td>UD</td>
<td></td>
<td>&gt;1000</td>
<td>16, 20</td>
</tr>
<tr>
<td>U937 (promonocytic)</td>
<td>UD</td>
<td></td>
<td>&gt;1000</td>
<td>16, 20</td>
</tr>
</tbody>
</table>

* The radioreceptor binding assay for all the cell lines was performed the same way as mentioned in the legend to Fig. 1A. The binding sites per cell and receptor affinity (Kd) for all cell types were calculated from binding data.

** IC50, the concentration of IL-13 toxin at which 50% inhibition of protein synthesis is observed compared to untreated cells; this was determined as described in “Materials and Methods.” The mean IC50 for individual tumors is shown and was determined from two to five experiments for five AIDS-KS cell lines.

Table 1). In contrast, normal HUVECs were plated in triplicate in gelatinized 100-mm Petri dishes, and the next day, IL-13 or IL13 toxin at various concentrations or control medium was added. The plates were incubated for 10 days. The medium was then removed, and colonies were fixed and stained with 0.25% crystal violet (Sigma Chemical Co.) in 25% ethyl alcohol. The colonies containing more than 50 cells were scored.

** Antitumor Activity of IL13-PE38QQR.** Human epidermoid carcinoma cells (3 × 106) obtained from American Type Culture Collection (Rockville, MD) were injected s.c. into 4–6-week-old female nude mice (Charles River Breeding Laboratories). After 7 days, the tumors were palpable and treated with IL13-PE38QQR (1.0 µg) or control excipient (0.2% human albumin serum in PBS) i.p. every day for 3 days. Tumors were measured, and volumes were calculated based on the following formula: Volume = Length × (Width)² × 0.4.

** Results and Discussion**

** AIDS-KS Cells Express High-Affinity IL-13R**

We found that all five KS cell lines examined expressed large numbers (2,400–14,500 sites/cell) of high-affinity (Kd = 124–525 pm) IL-13R (Fig. 1A and B; Table 1). In contrast, normal HUVECs that have been shown to respond to IL-13 (22) expressed lower numbers of IL-13R (<200 sites/cell; Table 1). Similarly, resting human T cells, EBV-immortalized B cells, and U937 promonocytic cell line did not show detectable levels of IL-13R (Table 1). To examine the interaction of IL-13R with IL-4 that has been proposed previously (16, 17), we examined whether IL-4 could compete for the binding of IL-13. It has been observed that in certain cell lines, IL-4 competes for the binding of IL-13 (16, 19, 20, 23). However,
as shown in Fig. 1C, IL-13 completely inhibited for the binding of $^{125}$I-labeled IL-13, whereas IL-4 modestly inhibited the binding of IL-13 on two AIDS-KS cell lines examined. This suggests that IL-13R does not interact significantly with IL-4 in AIDS-KS cells, and that IL-13R expression on AIDS-KS cells may be independent of IL-4R expression.

**Subunit Structure of IL-13R on AIDS-KS**

The subunit structure of IL-13R was investigated by cross-linking studies. As shown in Fig. 1D, $^{125}$I-labeled IL-13 cross-linked to one major protein migrating as a single band at $M_t \approx 83,000$ on two AIDS-KS cell lines, KS248 and NCB-59 (Fig. 1D, Lane 1, top and bottom). After subtracting the molecular weight of IL-13 ($M_M, 13,000$), the size of the major protein was estimated as $M_t \approx 70,000$. This cross-linked protein was specific IL-13 binding protein, given that no cross-linking was observed in the presence of a 500-fold molar excess of unlabeled IL-13 (Fig. 1D, Lane 2, top and bottom). Similar to the binding studies, IL-4 only partially displaced $^{125}$I-labeled IL-13 cross-linking to $M_t \approx 70,000$ protein (Fig. 1D, Lane 3, top and bottom). These data suggest that IL-13R on AIDS-KS cells are composed predominantly of a single $M_t \approx 70,000$ protein that binds the IL with high affinity.

**IL-13-PE38QQR Is Highly Cytotoxic to AIDS-KS Cells**

**Protein Synthesis Inhibition Assay.** We have recently produced a chimeric protein composed of IL-13 and a truncated form of *Pseudomonas* exotoxin (IL-13-PE38QQR), which was found to be potentially cytotoxic to IL-13R-positive solid tumor cells (18–20). The PE part of this chimeric protein is a two-domain protein: domain II catalyzes the translocation of the toxin into the cytosol, and domain III shuts off the protein synthesis by ADP ribosylating the elongation factor II that ultimately kills cells. Because, as shown above, AIDS-KS cells overexpress IL-13R, we
Table 2  In vitro inhibition of AIDS-KS cell growth by IL-13 and IL13-PE38QQR in a clonogenic assay

Results are expressed as percentage of colonies formed in treated cells compared to untreated cells. KS248, NCB-59, and HUVECs formed 88 ± 6, 210 ± 6, 66 ± 5 colonies (mean ± SD), respectively.

<table>
<thead>
<tr>
<th>Proteins</th>
<th>Colonies ± SD (% control)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>KS248</td>
</tr>
<tr>
<td>IL-13 (ng/ml)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>90 ± 6</td>
</tr>
<tr>
<td>10</td>
<td>79 ± 3</td>
</tr>
<tr>
<td>100</td>
<td>76 ± 1</td>
</tr>
<tr>
<td>1000</td>
<td>65 ± 1</td>
</tr>
<tr>
<td>IL13-PE38QQR (ng/ml)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>51 ± 2</td>
</tr>
<tr>
<td>5</td>
<td>22 ± 4</td>
</tr>
<tr>
<td>50</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>100</td>
<td>3 ± 1</td>
</tr>
<tr>
<td>200</td>
<td>0</td>
</tr>
</tbody>
</table>

Fig. 3  Antitumor activity of IL13-PE38QQR. Nude female mice (five in each group) were injected s.c. with A431 (3 × 10^6 cells) on day 0, and on days 7, 8, and 9 (arrows), they received either control excipient (○) or 1.0 μg IL13-PE38QQR (●). Bars, SD.

Table 2 In vitro inhibition of AIDS-KS cell growth by IL-13 and IL13-PE38QQR in a clonogenic assay

Results are expressed as percentage of colonies formed in treated cells compared to untreated cells. KS248, NCB-59, and HUVECs formed 88 ± 6, 210 ± 6, 66 ± 5 colonies (mean ± SD), respectively.

The IC50 by clonogenic assay was calculated to be approximately 1.2 and 7.0 ng/ml for KS248 and NCB-59 cell lines, respectively; however, HUVECs were not sensitive at all (IC50 not achieved).

next examined whether IL-13R on these cells could be targeted by IL-13 toxin. By utilizing IL13-PE38QQR, we observed that all five cultures of AIDS-KS cell lines were highly sensitive to the cytotoxic effect of IL-13 toxin as determined by protein synthesis inhibition assay (data shown for two cell lines, KS248 and NCB-59; Fig. 2, A and B). The 50% inhibition in protein synthesis (IC50) in five AIDS-KS cell lines was achieved between 3 and 270 ng/ml (60–5400 pm) of the chimeric toxin (Table 1). The cytotoxic activity of IL13-PE38QQR was blocked completely by an excess of IL-13 but not blocked significantly by an excess of IL-4, indicating that cytotoxicity mediated by IL-13 toxin is specific, and IL-13Rs on AIDS-KS cells are distinct from IL-4R and do not interact with IL-4 (Fig. 2, A and B). There are several other types of cells in which the toxic effect of IL13-PE38QQR could not be competed with IL-4. We demonstrated recently that IL-4 did not compete with the cytotoxic effect of IL13-PE38QQR in human renal cell carcinoma cells (20) and human glioma cells (19). In addition, we have also shown that IL-4 cannot compete for IL-13 binding in human renal cell carcinoma cells (16). Thus, these results agree with our previous observations.

The cytotoxicity of IL13-PE38QQR was also tested on normal HUVECs, resting and activated CD34+ bone marrow precursor cells, EBV-immortalized B cells, resting T cells, and monocytic cell lines. Consistent with the expression of low numbers of IL-13R (Table 1), IL13-PE38QQR was not cytotoxic (IC50 > 1000 ng/ml) to these cells (Fig. 2C: Table 1).

Clonogenic Assay. In vitro clonogenic assays were also performed in the presence of IL-13 or IL13-PE38QQR to examine the effect of these proteins on the proliferation of AIDS-KS cells. IL-13 by itself induced a modest inhibition of proliferation of AIDS-KS cells, indicating that IL-13R on AIDS-KS cells are functional (Table 2). On the other hand, IL-13 did not increase significantly. Control mice showed a continued increase in tumor size. These results demonstrate that IL13-PE38QQR also exerts in vivo antitumor activity.

To the best of our knowledge, this is the first demonstration of the expression of a large number of high-affinity IL-13R on AIDS-KS cells that are internalized after binding to the ligand. AIDS-KS cells are extremely sensitive to IL13-PE38QQR, and this cytotoxic activity is extremely specific, because an excess of recombinant IL-13 completely blocked the protein synthesis inhibition mediated by chimeric toxin. IL-4 did not compete significantly for the IL-13 binding as well as the cytotoxicity of IL-13 toxin. This indicates that the IL-13Rs on AIDS-KS cells do not exhibit any significant commonality with IL-4R, the characteristic that was attributed to many normal cells and some adenocarcinomas (17, 18, 23).

Furthermore, we observed that there was a positive correlation between the level of IL-13R expression and sensitivity to the antitumor activity of IL13-PE38QQR. Complete inhibition of colony formation was observed at 200 ng/ml (4.0 nM) IL-13 toxin. The IC50 of IL13-PE38QQR by clonogenic assay corroborated well with the IC50 determined by protein synthesis inhibition experiments. Similar to the protein synthesis assay, there was no effect of IL-13 toxin on colony formation of the endothelial cell line.

Next, we wished to examine the antitumor activity of IL13-PE38QQR in vivo against AIDS-KS. Unfortunately, three of the AIDS-KS cell lines implanted s.c. into nude, nude/beige, and nude irradiated mice did not develop into tumors consistently. Thus, in vivo antitumor activity of IL-13 toxin could not be evaluated against AIDS-KS. However, the antitumor activity of IL13-PE38QQR was evaluated by utilizing a human epidermoid carcinoma xenograft model. As shown in Fig. 3, IL13-PE38QQR-treated mice showed pronounced antitumor activity, and the tumor size did not increase significantly. Control mice showed a continued increase in tumor size. These results demonstrate that IL13-PE38QQR also exerts in vivo antitumor activity.
IL13-PE38QQR, except in KS54A cells. It is possible that the differential internalization rate, intracellular processing of the toxin, or both play a role. IL13-PE38QQR was only found to be cytotoxic to AIDS-KS cell lines and not to normal endothelial cells. In addition, human T and B cells, monocytes, and resting or growth factor-activated bone marrow cells were not sensitive to the cytotoxic effect of IL13-PE38QQR (20). The insensitivity of normal cells to IL13-PE38QQR is most probably due to the lack of or low number of IL-13R expression on these cells.

In conclusion, we have demonstrated that five out of five AIDS-KS cell lines express a large number of IL-13 receptors, and AIDS-KS cells are highly sensitive to a chimeric protein composed of IL-13 and Pseudomonas exotoxin. We have also demonstrated that IL13-PE38QQR has a significant antitumor activity against human cancer. Additional studies are ongoing to examine the expression of IL-13R in additional KS samples in vitro and in vivo. The specific probes or antibodies to IL-13R is currently not available. The availability of these reagents will help us address whether IL-13R on AIDS-KS cells constitutes an adequate model for KS therapy. Efforts are under way to grow KS cells in immunodeficient animals to evaluate the antitumor activity of IL13-PE38QQR.

Thus, IL-13 receptors may serve as a unique target for the delivery of cytotoxic agents such as Pseudomonas exotoxin or, alternatively, IL-13-directed gene therapy using growth modulatory genes, including tumor suppressor genes.

Acknowledgments
We thank Drs. S. Dhawan and T. Murata for reading the manuscript, and Pam Dover for excellent technical assistance.

References
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.

S R Husain, N I Obiri, P Gill, et al.

*Clin Cancer Res* 1997;3:151-156.

Updated version  Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/3/2/151

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/3/2/151. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.